Xaqiiqooyinka ku saabsan Tivicay (dolutegravir)

Maandooriyeyaasha HIV-ga ee loo yaqaan 'Optional First Option' ee Maraykanka

Tivicay (dolutegravir) waa daaweyn isdhexgal ah - daroogada daawada antiretroviral ee loo isticmaalo daaweynta HIV. Waxay ahayd tan labaad ee fasalka ah ee isdhexgalayaasha isdhexgalka si loo ansixiyo Maamulka Cuntada iyo Dawooyinka ee Maraykanka (FDA).

Tivicay waxaa la siiyey liisanka FDA ee Agoosto 12, 2013, si loogu isticmaalo dadka waaweyn iyo caruurta da'doodu tahay 12 ama ka weyn oo miisaankoodu yahay ugu yaraan 88 rodol (40kg) oo aan horey loogu daaweynin isdabajar midaysan.

(Tivicay looma oggolaanayo carruurta da'doodu ka yar tahay 12 jir, inkastoo baaritaanada Phase III clinical loo socdo si ay u qiimeeyaan amnigooda iyo waxtarkooda kooxda da'daas.)

Tivicay sidoo kale waa qayb ka mid ah hal mar-maalin, daroogo isku dhafan oo go'an, Triumeq , oo ay ku jiraan daroogada abacavir iyo lamivudine. Triumeq waxaa ansixiyay FDA August 22, 2014.

Daraasadaha Daraasada Caafimaadka

Baaritaanka VIKING-3 wuxuu muujiyey in Tivicay uu ahaa mid waxtar leh 63% bukaanno qaan-gaar ah oo iska caabin kala duwan leh ee daawooyinka HIV-ga ah, oo ay ku jiraan isdhexgalka kaadida Isentress (ratelgravir) iyo elvitegravir (laga helo hal kaniiniga, daroogo isku-dhafan ah, Stribild ) .

Daraasad SINGLE ah ayaa shaaca ka qaaday in bukaanada Tivicay ay yeesheen dhacdooyin hoose oo ah joojinta joojinta sababtoo ah saameynta xun ee daroogada ka badan tan Atripla (tenofovir + emtricitabine + efavirenz). Ka dib 48 toddobaad, 2% maadooyinka ku saabsan nidaamka Tivicay-ku-salaysan ayaa joojiyay daaweynta illaa 10% dadka qaada Atripla.

Qiyaasta

Intaa waxaa dheer, carruurta ay wadaagaan Sustiva (efavirenz), Aptivus (tipranavir) + Norvir (ritonavir), Lexiva (fosamprenavir) + Norvir (ritonavir), ama rifampin, qiyaasta Tivicay waa 50mg, laba jeer maalintii.

Ilaa hadda lama yaqaan haddii Tivicay ay wax ku ool u tahay carruurta leh iskudhaf diidmo oo la xidhiidha caabbinta.

Maamulka Daweynta

Tivicay waxaa laga yaabaa in la qaato ama aan cunto lahayn, iyo wakhti kasta oo maalinta ah.

Saameynada Caadiga ah

Dhibaatooyinka ugu badan ee la ogaaday (ee ku dhaca 2% ama ka yar kiisaska) waa:

Isdhexgalka Daroogada ama La'aanta

Tikosyn (dofetilide), oo loo isticmaalo daaweynta miyir la'aanta (wadnaha aan caadi ahayn), ayaa ka hortagaya isticmaalka Tivicay.

Si looga fogaado isdhexgalka mukhadaraadka daroogada ee suurogalka ah, kugula tali dhakhtarkaaga inaad qaadatid mid ka mid ah daawooyinka soo socda:

Tixgelinno

> Ilo:

Maktabadda Qaranka ee Dawada ee Maraykanka. "TIVICAY (dolutegravir sodium) kiniin, filim ku dhegay." Bethesda, Maryland; dib loo eegay bishii Agoosto 2013.

ViiV Daryeel Caafimaad. "ViiV Healthcare waxay heshaa ogolaanshaha FDA ee Triumeq." London, England; saxaafadeed ayaa soo saartay 22 Agoosto 2014.

Walmsley S .; Antela, A .; Clumeck, N .; et al. "Dolutegravir (DTG; S / GSK1349572) + abacavir / lamivudine hal mar maalinkiiba ayuu ka sarreeyaa tobanofovir / emtricitabine / efavirenz: natiijooyinka 48-todobaad - SINGLE (ING114467)." Shirka Shirwaynaha 52aad ee Aaladaha Antimicrobial iyo Chemotherapy. San Francisco; Sebtembar 9-12, 2012; Abstract H-556b.

Nichols, G .; Grossberg, R .; Lazzarin, A .; et al. "Waxqabadka fayruska ee fayadhowrka ee mawduucyada ku lug leh ku-guul dareysiga xukunka ku-meel-gaadhka ah ee ku-meel-gaadhka ah: Saacada 24-aad Wejiga 3-Natiijooyinka laga bilaabo VIKING-3." Shirkii 11aad ee Caalamiga ah ee Daweynta Dawooyinka ee HIV-ga (HIV11). Glasgow, Scotland; Nofeembar 11-15, 2012; Abstract O232.